Zetia vs Losartan Side Effects: Which Is Right for You as a Woman?

What These Two Drugs Actually Do (and Why Comparing Them Is Complicated)

Zetia and losartan work on completely different physiological targets, so a direct head-to-head side-effect trial does not exist. No randomized controlled trial has enrolled women and asked, "Which of these two drugs causes fewer problems?" What does exist are large outcome trials for each drug individually, plus decades of post-marketing safety data. That distinction matters: the comparisons below are synthesized across separate trials and clinical experience, not from a single head-to-head study.

Ezetimibe (Zetia): Mechanism and Target Population

Ezetimibe blocks the NPC1L1 transporter in the intestinal brush border, cutting the amount of dietary and biliary cholesterol absorbed into the bloodstream. A 10 mg daily dose reduces LDL-C by approximately 18 to 20% as monotherapy, and when added to a statin, the combination typically achieves an additional 20 to 25% LDL reduction on top of the statin alone.

The primary candidates for ezetimibe are women who:

• Cannot tolerate a statin at the dose needed to reach their LDL goal
• Have familial hypercholesterolemia and need LDL lowering beyond what one drug provides
• Had an acute coronary syndrome (ACS) and need aggressive secondary prevention
• Have PCOS-related dyslipidemia where LDL and non-HDL-C remain elevated despite lifestyle changes

Losartan (Cozaar): Mechanism and Target Population

Losartan blocks the AT1 receptor for angiotensin II, preventing the vasoconstriction and aldosterone release that angiotensin II normally drives. The result is lower blood pressure, reduced afterload on the heart, and, in women with diabetic nephropathy, slower progression of proteinuria.

Women who are most likely to receive losartan include those with:

• Essential hypertension, particularly if ACE-inhibitor cough is intolerable
• Type 2 diabetes with microalbuminuria or proteinuria
• Heart failure with reduced ejection fraction
• Hypertension secondary to PCOS (where insulin resistance and sympathetic activation raise blood pressure)
• Postmenopausal hypertension, which tends to be more salt-sensitive and renin-independent than premenopausal hypertension

Side-Effect Profiles: What the Evidence Shows for Women

Side effects are where these two drugs diverge most clearly. The overall burden for ezetimibe is low. The overall burden for losartan is also low by antihypertensive standards, but the adverse-effect categories differ enough that you and your clinician should weigh them separately.

Ezetimibe Side Effects

The most consistent side effects reported in ezetimibe trials and post-marketing data are:

• Musculoskeletal pain: Myalgia occurs in roughly 5 to 7% of users, though the causal attribution is complicated because ezetimibe is almost always co-prescribed with a statin, and statins themselves cause myalgia in up to 10% of patients. A 2016 systematic review in the European Journal of Preventive Cardiology found that ezetimibe monotherapy did not significantly increase muscle enzyme (CK) levels compared with placebo.
• Gastrointestinal symptoms: Diarrhea, abdominal pain, and flatulence each occur in 3 to 5% of users. These tend to be mild and resolve within the first few weeks.
• Liver enzyme elevation: Transaminase elevations above three times the upper limit of normal occur in fewer than 1% of users on ezetimibe alone; the rate rises slightly when combined with a statin.
• Headache: Reported in about 4% of trial participants; comparable to placebo rates.

Ezetimibe carries no angioedema risk, no first-dose hypotension, and no renal function concerns in healthy kidneys.

Losartan Side Effects

Losartan's side-effect profile reflects its mechanism:

• Dizziness and hypotension: First-dose and ongoing dizziness occur in 3 to 7% of patients. In the LIFE trial, dizziness was the most commonly reported adverse effect in the losartan arm, affecting approximately 8.6% of participants. Women's autonomic responses to blood pressure lowering differ from men's, and postmenopausal women with pre-existing orthostatic hypotension may notice this more acutely.
• Hyperkalemia: Potassium retention is a class effect of all ARBs. Risk is amplified in women with chronic kidney disease, those on potassium-sparing diuretics, or those taking NSAIDs regularly, a pattern common in women managing arthritis or dysmenorrhea.
• Upper respiratory symptoms: Mild nasal congestion and upper respiratory tract infections are reported in approximately 8% of users. This is distinct from the dry cough seen with ACE inhibitors, which affects women at roughly twice the rate it affects men and is one reason many women are switched from ACE inhibitors to losartan in the first place.
• Renal function changes: Serum creatinine may rise modestly in the first weeks of therapy, especially in women with renovascular disease or volume depletion.
• Angioedema: Rare (estimated 0.1 to 0.4% risk), but women develop ACE-inhibitor-induced angioedema at higher rates than men. ARB-related angioedema is less common but still a class concern, particularly in women with prior ACE-inhibitor angioedema. The FDA prescribing information for losartan notes this risk explicitly.

How Hormonal Status Changes the Picture

During the Reproductive Years

Estrogen and progesterone influence both lipid metabolism and the renin-angiotensin-aldosterone system (RAAS). During the follicular phase, estrogen modestly increases HDL-C and lowers LDL-C. Progesterone can partially offset that effect in the luteal phase. For a woman in her 30s on ezetimibe for familial hypercholesterolemia, her LDL response may vary slightly across her cycle. The clinical magnitude of this variation is small, but it is one reason lipid panels are best drawn at a standardized cycle day when possible.

The RAAS is also cycle-dependent: aldosterone and renin activity peak in the mid-luteal phase. A woman starting losartan might find her blood pressure response varies slightly across her cycle, though this is rarely large enough to require dose adjustment in clinical practice.

Perimenopause

The perimenopausal transition brings a well-documented worsening of the lipid profile. LDL-C rises by an average of 10 to 14 mg/dL in the years surrounding the final menstrual period, a change driven largely by falling estradiol rather than aging alone. Blood pressure also rises during perimenopause, linked to declining estrogen's vasodilatory effects and increasing sympathetic tone. This is the life stage where many women first need either ezetimibe (if statin-managed LDL is still above goal) or losartan (if blood pressure crosses treatment thresholds).

Postmenopause

Postmenopausal women have a cardiovascular risk profile that converges toward male rates. The IMPROVE-IT trial enrolled only approximately 24% women overall, which limits conclusions about sex-specific MACE outcomes for ezetimibe. In the women enrolled, the relative risk reduction was numerically similar to that in men, but the trial was not powered for a sex-stratified analysis. That is an evidence gap worth naming plainly.

Losartan data in postmenopausal women is somewhat richer. The LIFE trial included women with hypertension and left ventricular hypertrophy (LVH), and the losartan arm showed a 13% reduction in the composite primary endpoint of cardiovascular death, myocardial infarction, or stroke compared with atenolol. In a sex-stratified analysis from LIFE, women appeared to derive at least as much stroke-reduction benefit as men, with a particularly notable advantage over atenolol for stroke prevention.

Pregnancy, Lactation, and Contraception: Required Reading

Both drugs must be stopped before you try to conceive.

Losartan in Pregnancy

Losartan carries an FDA Pregnancy Category D designation. ARBs are known human teratogens. Exposure during the second and third trimesters causes fetal renal tubular dysplasia, oligohydramnios, neonatal renal failure, skull hypoplasia, and death. Even first-trimester exposure has been associated with cardiovascular and central nervous system malformations in some cohort studies. If you are prescribed losartan and are of reproductive age, effective contraception is not optional; it is clinically required. Any unplanned pregnancy should be reported immediately so your provider can switch you to a pregnancy-compatible antihypertensive such as labetalol, nifedipine, or methyldopa.

Losartan and its active metabolite E3174 transfer into breast milk in animal studies. Human lactation data are limited. Most guidelines recommend avoiding ARBs while breastfeeding and using alternatives with better safety records in lactation.

Ezetimibe in Pregnancy

Ezetimibe has no formal FDA pregnancy category under the old system (it was approved after the 2015 labeling change). The FDA prescribing information states that animal reproductive studies showed adverse developmental effects, and there are no adequate human data. Because hypercholesterolemia is not an acute emergency and fetal cholesterol synthesis is critical for neural development, ezetimibe is generally discontinued before conception and throughout pregnancy. Cholesterol synthesis inhibitors and absorption blockers are both considered contraindicated in pregnancy by most guidelines.

Ezetimibe passes into human breast milk at low levels; the clinical significance is unknown. Most clinicians advise stopping ezetimibe while breastfeeding, substituting bile acid sequestrants (which are not absorbed) as the only class considered relatively safe in lactation.

Trying to Conceive

If you have PCOS-related dyslipidemia and hypertension and are actively trying to conceive, both medications should be stopped. Your clinician should have a documented pre-conception plan that addresses blood pressure management and lipid risk during pregnancy without these agents.

Women-Specific Conditions These Drugs Touch

PCOS

Women with PCOS carry a substantially elevated cardiometabolic risk. Dyslipidemia (high triglycerides, low HDL-C, and an atherogenic small-dense LDL pattern) is present in up to 70% of women with PCOS. Ezetimibe is a reasonable add-on for PCOS-related LDL elevation when lifestyle change and metformin have been optimized. Losartan is relevant for the subset of women with PCOS who develop hypertension or microalbuminuria secondary to insulin resistance.

Hypertension in Perimenopausal and Postmenopausal Women

Hypertension affects more than 70% of women over age 65, making it one of the most common conditions a postmenopausal woman will manage. Losartan fits well in women who experienced ACE-inhibitor cough (more common in women, particularly women of Asian descent) or who need a renal-protective agent alongside their antihypertensive.

Thyroid Disease and Lipids

Hypothyroidism elevates LDL-C, and women are diagnosed with hypothyroidism at five times the rate of men. An undertreated hypothyroid woman may have LDL-C that looks refractory to statins, when the real fix is optimizing thyroid replacement. Ezetimibe should not be added before thyroid status is confirmed to be well-managed.

Menopausal Hormone Therapy Interactions

Menopausal hormone therapy (MHT) with oral estrogen raises triglycerides and modestly lowers LDL-C. It also mildly activates the RAAS and can raise blood pressure in susceptible women. A woman who starts oral MHT and sees her blood pressure climb may need dose titration of losartan. Transdermal estrogen has a smaller effect on triglycerides and the RAAS, which is one clinical reason to prefer the transdermal route in women with existing lipid or blood pressure concerns.

Who This Is Right For and Who Should Reconsider

The framework below is a clinical decision aid, not a prescription. Use it as a starting point for conversation with your provider.

Ezetimibe Is Likely the Right Conversation If You:

• Have an LDL-C above your goal despite a maximally tolerated statin
• Cannot tolerate any statin due to myalgia or liver enzyme elevation
• Have familial hypercholesterolemia (LDL-C above 190 mg/dL at baseline)
• Had an ACS and are in secondary prevention with a cardiologist
• Have PCOS-related dyslipidemia and are not pregnant or breastfeeding
• Are perimenopausal and have seen your LDL rise despite stable lifestyle habits
• Your primary cardiometabolic problem is elevated cholesterol, not elevated blood pressure

Ezetimibe Is Probably Not the Right Fit If You:

• Have blood pressure above 130/80 mmHg as your primary cardiometabolic concern
• Are pregnant, trying to conceive, or breastfeeding
• Have normal LDL-C and no atherosclerotic risk requiring LDL reduction

Losartan Is Likely the Right Conversation If You:

• Have a confirmed diagnosis of hypertension (sustained BP above 130/80 mmHg per 2023 ACC/AHA guidelines)
• Experienced an intolerable dry cough on an ACE inhibitor
• Have diabetic kidney disease or microalbuminuria
• Have heart failure with reduced ejection fraction and are on a guideline-directed regimen
• Have hypertension with LVH and want a drug class with documented stroke-reduction data

Losartan Is Not Appropriate If You:

• Are pregnant or planning pregnancy in the near term
• Are breastfeeding (limited safety data, safer alternatives exist)
• Have bilateral renal artery stenosis
• Already have significant hyperkalemia (serum potassium above 5.0 mEq/L)
• Have a prior history of angioedema with any ARB or ACE inhibitor

Can You Take Both?

Yes, and many women do. A postmenopausal woman managing both hypertension and elevated LDL after a cardiac event might reasonably be on rosuvastatin, ezetimibe, and losartan simultaneously. These drugs do not have significant pharmacokinetic interactions with each other. The combination addresses two separate pathways, lipid metabolism and blood pressure, that are both part of overall cardiovascular risk reduction.

The main monitoring consideration when combining them is kidney function and electrolytes: losartan can raise potassium, and any added agents that also raise potassium (such as a potassium-sparing diuretic) should be tracked carefully.

Monitoring What Matters: A Women-Focused Checklist

On ezetimibe:

• LDL-C, HDL-C, and non-HDL-C at 6 to 12 weeks after starting or changing dose
• Liver function tests at baseline and if symptoms develop (routine monitoring not required by current guidelines)
• CK only if muscle symptoms appear, not routinely
• In PCOS: full lipid panel including triglycerides and fasting glucose, since the metabolic picture is broader than LDL alone

On losartan:

• Blood pressure in both arms at initiation, then after each dose change
• Basic metabolic panel (serum creatinine, potassium, sodium) at 2 to 4 weeks after starting, then every 6 to 12 months
• Urine albumin-to-creatinine ratio annually if you have diabetes or CKD
• In perimenopause: blood pressure measured outside the office if possible (home readings) because of white-coat variability

The Evidence Gap You Deserve to Know About

Women made up only about 24% of IMPROVE-IT participants and a similar minority in most foundational cardiovascular outcome trials. LIFE enrolled more women (roughly 54% of its 9,193 participants), making it one of the few large cardiovascular trials where women were not a minority. That difference matters: LIFE's data in women is more directly applicable than IMPROVE-IT's, where findings are extrapolated from a majority-male dataset.

This is not a criticism of any particular drug. It reflects a decades-long pattern of underenrolling women in cardiovascular trials that is slowly being corrected. When your clinician quotes a risk-reduction figure for ezetimibe, ask whether that figure is from the full trial or from the women's subgroup. The answer shapes how confidently you can apply it to yourself.